Biopharmaceutical company Erasca, Inc. (ERAS) shares plunged 36.6% in pre-market trading after the company released early clinical trial data for its experimental cancer therapy.

老虎证券2026/04/28 09:05

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This significant fluctuation in stock price directly reflects the market’s assessment of the preliminary research results. The company is focused on developing innovative therapies for refractory cancers, and the early-stage trial results announced this time have attracted great attention from investors. Drastic price movements usually indicate a market repricing of the outlook for clinical data.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biopharmaceutical company Erasca, Inc. (ERAS) shares plunged 36.6% in pre-market trading after the company released early clinical trial data for its experimental cancer therapy.

You may also like

Crypto prices